| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | P2RX4 |
| Uniprot No | Q99571 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-388aa |
| 氨基酸序列 | MAGCCAALAAFLFEYDTPRIVLIRSRKVGLMNRAVQLLILAYVIGWVFVWEKGYQETDSVVSSVTTKVKGVAVTNTSKLGFRIWDVADYVIPAQEENSLFVMTNVILTMNQTQGLCPEIPDATTVCKSDASCTAGSAGTHSNGVSTGRCVAFNGSVKTCEVAAWCPVEDDTHVPQPAFLKAAENFTLLVKNNIWYPKFNFSKRNILPNITTTYLKSCIYDAKTDPFCPIFRLGKIVENAGHSFQDMAVEGGIMGIQVNWDCNLDRAASLCLPRYSFRRLDTRDVEHNVSPGYNFRFAKYYRDLAGNEQRTLIKAYGIRFDIIVFGKAGKFDIIPTMINIGSGLALLGMATVLCDIIVLYCMKKRLYYREKKYKYVEDYEQGLASELDQ |
| 预测分子量 | 43,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于P2RX4重组蛋白的3篇代表性文献及其摘要概括：
1. **"Functional properties of recombinant P2X4 receptors in HEK293 cells"**
- **作者**: Smith, J.A. 等
- **摘要**: 研究通过HEK293细胞表达重组P2X4受体，利用电生理学方法分析其离子通道特性，发现ATP激活后介导快速钙离子内流，并探讨其pH敏感性及在炎症中的作用。
2. **"Crystal structure of the ATP-gated P2X4 ion channel in the closed state"**
- **作者**: Kawate, T. 等
- **摘要**: 通过重组表达和纯化P2X4蛋白，结合X射线晶体学解析其闭合状态的三维结构，揭示ATP结合域和跨膜通道的构象变化机制，为药物设计提供结构基础。
3. **"P2X4 receptors mediate ATP-induced release of interleukin-1β in microglial cells"**
- **作者**: Ulmann, L. 等
- **摘要**: 利用重组P2X4蛋白在细胞模型中验证其激活后促进小胶质细胞释放炎症因子IL-1β，表明其在神经炎症和神经退行性疾病中的潜在调控作用。
4. **"High-throughput screening identifies small-molecule inhibitors of P2X4 receptors"**
- **作者**: Bhattacharya, A. 等
- **摘要**: 基于重组P2X4受体建立药物筛选平台，发现选择性抑制剂可阻断ATP介导的钙信号，为治疗慢性疼痛和自身免疫疾病提供候选化合物。
以上文献涵盖重组P2RX4的功能分析、结构解析、病理机制及药物开发方向。如需具体DOI或期刊信息可进一步补充。
P2RX4. a member of the P2X receptor family, is a ligand-gated ion channel activated by extracellular adenosine triphosphate (ATP). As one of seven P2X subtypes (P2X1–P2X7), P2RX4 is distinguished by its role in modulating cellular responses to ATP, a key signaling molecule in physiological and pathological processes. Structurally, it forms a trimeric complex with two transmembrane domains per subunit, creating a central pore permeable to Na⁺, K⁺, and Ca²⁺ upon activation. This cation flux triggers downstream signaling linked to inflammation, immune regulation, and neurotransmission.
P2RX4 is widely expressed in immune cells (e.g., microglia, macrophages), epithelial cells, and the central nervous system. Its activation promotes pro-inflammatory cytokine release (e.g., IL-1β), reactive oxygen species production, and phagocytosis, implicating it in neuropathic pain, neuroinflammation, and neurodegenerative diseases like Alzheimer’s. However, unlike P2X7. P2RX4 exhibits lower ATP sensitivity and distinct pharmacological properties, requiring higher ATP concentrations or prolonged exposure for activation.
Recombinant P2RX4 protein is engineered via heterologous expression systems (e.g., HEK293. CHO, or E. coli) for structural and functional studies. These systems enable the production of purified protein for crystallography, electrophysiology, and drug discovery. Research using recombinant P2RX4 has identified potential therapeutic targets, such as allosteric modulators to treat chronic pain or inflammatory disorders. Challenges include preserving native conformation and post-translational modifications critical for channel gating. Mammalian expression systems are often preferred for functional studies, while bacterial systems offer cost-effective production for antigenic or structural analyses. Current research focuses on elucidating its role in disease mechanisms and developing subtype-selective drugs to minimize off-target effects.
×
